Skip to main content

Clearing Rosacea

Galderma strives for clearer skin for rosacea patients. There are many great options for you and your healthcare provider to discuss about your rosacea treatment. The bottom line is that clearer skin is possible, and you should set your expectations high and work with your healthcare team to get there.

Let’s S.T.O.P. to Talk about Rosacea

S.T.O.P. is a set of guiding principles that patients can use to discuss their rosacea and treatment goals with their healthcare provider. This approach to treatment can help people suffering from rosacea achieve clearer results.

  1. S

    Before you can improve rosacea, you need to recognize the signs and symptoms of rosacea.

  2. T

    By identifying and understanding the triggers of your rosacea, you can help prevent breakouts and redness.

  3. O

    When battling rosacea, it’s important to have an outcome defined in your treatment to give you an obtainable goal to track against.

  4. P

    To reach your desired outcome, you must work closely with your healthcare provider to outline a clear plan of action that supports your lifestyle and helps you achieve clearer results.

Take the Rosacea Quiz Now

Aim for Clear Results

The Investigator’s Global Assessment (IGA) is a way to numerically score and define rosacea severity. Patients and healthcare providers can aim for measurable rosacea results by using the IGA as a tool to track treatment progress.

Man with clear results

Clear results (IGA 0) are defined as:

  • No bumps or blemishes (papules and/or pustules)
  • No redness (erythema or mild residual erythema)
  • No visible blood vessels (telangiectasia or mild to moderate telangiectasia)
Man with almost clear results

Almost Clear results (IGA 1) are defined as:

  • Rare bumps or blemishes (papules and/or pustules)
  • Redness (residual to mild erythema)
  • Visible blood vessels (mild to moderate telangiectasia)

Studies have shown that rosacea patients who achieve “Clear” (IGA 0) not only experience a more complete reduction in inflammatory lesions compared with patients who achieve ‘almost clear’ (IGA 1), but also achieve an extended time to relapse that is associated with an improved quality of life.10

Important Safety Information for ORACEA® (doxycycline) 40 mg* Capsules

Indication: ORACEA Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established. Click here to view the full prescribing information for ORACEA Capsules.

*30 mg immediate release & 10 mg delayed release beads

Important Safety Information for EPSOLAY® (benzoyl peroxide) Cream, 5%

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

Important Safety Information for SOOLANTRA® (ivermectin) Cream, 1%

Indication: SOOLANTRA Cream is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence ≤ 1 %) included skin burning sensation and skin irritation.

Important Safety Information for MIRVASO® (brimonidine) topical gel, 0.33%†

Indication: MIRVASO Gel is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha‐2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use. Click here to view full prescribing information for MIRVASO Gel.

†Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Select a Brand for Prescribing and Safety Information:

*30 mg immediate release & 10 mg delayed release beads
†Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

© 2023 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective owners.
This site is intended for U.S. audiences only. Information in this website is not intended as medical advice. Talk to your doctor about medical concerns.

Galderma logo